

Division of Workers' Compensation Pharmacy and Therapeutics Committee

July 15, 2026
12:30pm to 2:30pm



State of California
Gavin Newsom
Governor

Agenda

- **Welcome and Introductions**
Suzanne Honor-Vangerov, Legal Counsel, DWC
- **Approval of April 15, 2026 Meeting Minutes**
Dr. Raymond Meister, Executive Medical Director, DWC
- **Discussion:**
 - MTUS v14 RxCUI List – *Kevin Gorospe Pharm D*
 - GLP-1 Submitted ICD-10 – *Kevin Gorospe Pharm D*
 - Proton Pump Inhibitor Days Supply – *Kevin Gorospe Pharm D*
 - Anticonvulsant and Migraine Drugs – *Kevin Gorospe Pharm D*
 - Drugs to Review and Other Projects – *Kevin Gorospe Pharm D*
- **Additional Public Comments**
- **Review of Committee Recommendations**
- **Adjourn**

Welcome and Introductions

Suzanne Honor-Vangerov
Legal Counsel, DWC

Approval of April 15, 2026 Meeting Minutes

Dr. Raymond Meister
Executive Medical Director, DWC

MTUS v14 RxCUI List

J. Kevin Gorospe, PharmD, DWC Consultant

RxCUI Additions

Drug Ingredient	Reference Brand Name	Exempt/Non-Exempt*	Special Fill	Peri-Op	Drug Class
atogepant	QULIPTA	Exempt	Not Applicable	Not Applicable	Migraine Products
atogepant	QULIPTA	Exempt	Not Applicable	Not Applicable	Migraine Products
atogepant	QULIPTA	Exempt	Not Applicable	Not Applicable	Migraine Products
lacosamide	VIMPAT	Non-Exempt	Not Applicable	Not Applicable	Anticonvulsants
lasmiditan	REYVOW	Non-Exempt	4 Days	Not Applicable	Migraine Products
magnesium sulfate	Not Applicable	Non-Exempt	Not Applicable	Not Applicable	Minerals & Electrolytes
rimegepant	NURTEC ODT	Non-Exempt	4 days	Not Applicable	Migraine Products
ubrogepant	UBRELVY	Exempt	Not-Applicable	Not-Applicable	Migraine Products
ubrogepant	UBRELVY	Exempt	Not-Applicable	Not-Applicable	Migraine Products
zavegepant (nasal)	ZAVPRET	Non-Exempt	4 Days	Not Applicable	Migraine Products

Drug Ingredient	Reference in ACOEM Guidelines	Route of Administration	Dosage Form	Strength	RxCUI
atogepant	(R) Traumatic Brain Injury	Oral	Tablet	10 MG	2571836
atogepant	(R) Traumatic Brain Injury	Oral	Tablet	30 MG	2571844
atogepant	(R) Traumatic Brain Injury	Oral	Tablet	60 MG	2571848
lacosamide	(NR, X) Traumatic Brain Injury	Oral	ALL ORAL DOSAGE FORMS	ALL STRENGTHS	1162529
lasmiditan	(R) Traumatic Brain Injury	Oral	ALL ORAL DOSAGE FORMS	ALL STRENGTHS	2256934
magnesium sulfate	(X) Taumatic Brain Injury	Oral	ALL ORAL DOSAGE FORMS	ALL STRENGTHS	1158057
rimegepant	(R) Traumatic Brain Injury	Oral	ALL ORAL DOSAGE FORMS	ALL STRENGTHS	2618948
ubrogepant	(R) Traumatic Brain Injury	Oral	Tablet	50 MG	2268229
ubrogepant	(R) Traumatic Brain Injury	Oral	Tablet	100 MG	2268221
zavegepant (nasal)	(R) Traumatic Brain Injury	Nasal	NASAL DOSAGE FORM	ALL STRENGTHS	2637972

RxCUI List Changes

- Changes in RxCUI and consolidation of ingredient listings

Drug Ingredient	Reference Brand Name	Exempt/Non-Exempt*	Special Fill	Peri-Op	Drug Class
gabapentin (once-daily)	GRALISE	Non-Exempt	Not Applicable	Not Applicable	Psychotherapeutic and Neurological Agents - Misc
rivastigmine tartrate	EXELON	Non-Exempt	Not Applicable	Not Applicable	Psychotherapeutic and Neurological Agents - Misc.
rivastigmine	EXELON	Non-Exempt	Not Applicable	Not Applicable	Psychotherapeutic and Neurological Agents - Misc.

Drug Ingredient	Reference in ACOEM Guidelines	Route of Administration	Dosage Form	Strength	RxCUI	Notes
gabapentin (once-daily)	(X) Anxiety Disorders (X) Chronic Pain (X) Hip and Groin Disorders (X) Post-Traumatic Stress Disorder	Oral	ALL ORAL DOSAGE FORMS	ALL STRENGTHS	1172653	RxCUI updated to be specific for Gralise
rivastigmine tartrate	(R) Traumatic Brain Injury	Oral	ALL ORAL DOSAGE FORMS	ALL STRENGTHS	1157971	Consolidated under single RxCUI
rivastigmine	(R) Traumatic Brain Injury	Topical	ALL TOPICAL DOSAGE FORMS	ALL STRENGTHS	1157973	Consolidated under single RxCUI

RxCUI Product Deletion

Drug Ingredient	Reference Brand Name	Exempt/Non-Exempt*	Route of Administration	Dosage Form	Strength	RxCUI	Notes
ibuprofen	MOTRIN	Exempt	Oral	Tablet	300 MG	197804	Deleted based on April 2026 P&T vote

Committee Discussion

Public Comments

GLP1 Submitted ICD10

J. Kevin Gorospe, PharmD
DWC Consultant



State of California
Gavin Newsom
Governor

GLP-1 Background

- Previous P&T meetings noted use of GLP-1 products.
- GLP-1 or Glucagon-Like Peptide 1 drugs mimic the body's endogenous hormone.
- GLP-1 actions in the body include
 - Stimulates insulin secretion
 - Suppresses glucagon secretion
 - Slows gastric emptying
 - Increases satiety

GLP-1 Drug Indications

- Due to their effects on insulin and glucagon, GLP-1 drugs were initially approved by the FDA for use in type 2 diabetes starting in 2005.
- It was noted that patients using GLP-1 drugs lost weight, likely due to affects on gastric emptying and increased satiety.
- First FDA GLP-1 approval for weight loss occurred in 2014.
- Additional drugs followed with initial FDA approval for use in type 2 diabetes and weight loss
- Currently 13 brand drug and 2 generically available drugs

Generic Name	Brand Name	Indication	Launch
exenatide	BYETTA	Diabetes	2005 April
liraglutide	VICTOZA	Diabetes	2010 January
exenatide	BYDURION	Diabetes	2012 January
liraglutide	SAXENDA	Weight Loss	2014 December
albiglutide	TANZEUM	Diabetes	2016 April
semaglutide	OZEMPIC	Diabetes	2017 December
exenatide	BYDURION BCISE	Diabetes	2017 October
semaglutide	RYBELSUS	Diabetes (oral)	2020 January
lixisenatide	ADLYXIN	Diabetes	2020 July
semaglutide	WEGOVY	Weight Loss	2021 June
tirzepatide	MOUNJARO	Diabetes	2022 May
tirzepatide	ZEPBOUND	Weight Loss	2023 November
liraglutide	liraglutide	Diabetes	2024 December
exenatide	exenatide	Diabetes	2024 November
dulaglutide	TRULICITY	Diabetes	2024 September
liraglutide	liraglutide	Weight Loss	2025 August

GLP-1 Claim Diagnosis

- GLP-1 users
 - Data identified 32,796 Individual Workers (IWs) using these drugs over the 2-year period
 - Data is de-identified and the “Claim ID” is used as a proxy to link IW claims
- Diagnosis information was pulled from their records over a 2-year (2023-2024) period.
 - Information was pulled from primary and secondary diagnosis on the claim
 - IWs could have multiple and duplicative ICD-10s therefore raw counts of ICD-10s did not provide statistical value
 - Keywords, “diabetes”, “obesity”, “overweight”, were used to identify ICD-10 use
 - Other ICD-10 keywords “body mass”, “bariatric”, “hyperglycemia” were not found in the data

GLP-1 Claim Diagnosis (cont.)

- Based on keywords in ICD description, of the 32,796 IWs
 - 1,039 had a “diabetes” related ICD-10
 - 435 had an “obesity” related ICD-10
 - 71 had an “overweight” related ICD-10
 - 53 had both “diabetes” and “obesity”
 - 14 had both “diabetes” and “overweight”
 - 3 had all three – “diabetes”, “obesity”, “overweight”

Follow-up

- There may be non-GLP-1 users in the data based on the total number.
- Staff will run the data again to refine the data pull and will report back the results and any changes at the next meeting.

Committee Discussion

Public Comments

PPI Days Supply

J. Kevin Gorospe, PharmD

DWC Consultant

Proton Pump Inhibitor Background

- Proton Pump Inhibitors or PPIs have a variety of indications for use
 - Gastroesophageal Reflux Disease (GERD)
 - Peptic Ulcer Disease (PUD)
 - Helicobacter pylori (H. pylori) Infection
 - NSAID-Induced Ulcers
 - Hypersecretory Conditions
 - Gastrointestinal Bleeding Prevention
- The recommended duration of therapy for PPIs is 4 to 8 weeks.

PPI Claims Days Supply

- Pharmacy claims data for a 2-year period (2023-2024) was used to aggregate Days Supply
- Summary data does not delineate consecutive days use from multiple period use.
 - For example, if an IW used a PPI for 30 days, then stopped for 1 month and then used for another 60 days, use would show as a total of 90 days in the data.

Data Issues

- 17,135 Individual Workers (IWs) were identified
 - Of these 9,196 appeared to have total days supply greater than 60 days
- The data appears to have errors as there are total days supply that exceed a 2-year period.
- The totals provided may be number of units dispensed and not days.
- However, the totals also appear to exceed, in some instances, the potential total units dispensed in a 2-year period.
- There could be errors in the provider submitted data and staff will be working to clean-up the data and provide an updated review at the next P&T meeting

Follow-up (GLP-1)

- There may be non-GLP-1 users in the data based on the total number.
- Staff will run the data again to refine the data pull and will report back the results and any changes at the next meeting.

Committee Discussion

Public Comments

Anticonvulsant and Migraine Drugs

J. Kevin Gorospe, PharmD

DWC Consultant

Anticonvulsant and Migraine Drugs

- The drugs for review were identified using the MTUS Drug Class values of “Anticonvulsants” and “Migraine Products”

Drug Ingredient	Drug Ingredient
almotriptan malate	oxcarbazepine
atogepant	phenytoin; phenytoin sodium
carbamazepine	pregabalin
clonazepam	pregabalin (once-daily)
dihydroergotamine mesylate	rimegepant
divalproex sodium	rizatriptan benzoate
eletriptan hydrobromide	sumatriptan succinate
frovatriptan succinate	tiagabine hcl
gabapentin	topiramate
lacosamide	ubrogepant
lamotrigine	valproic acid
lasmiditan	zavegepant (nasal)
levetiracetam	zolmitriptan
naratriptan hcl	zonisamide

Pharmacy Utilization

- Five drugs (by generic description) make up the top 20 drugs by amount paid.
- Pregabalin and gabapentin are dominate in billed lines (claims) and first and third in amount paid.

Generic Name	Bill Lines	Paid
pregabalin	13,791	\$2,351,052.22
rimegepant sulfate	1057	\$1,831,791.08
gabapentin (incl. encarbil)	46,763	\$1,296,589.77
ubrogepant	427	\$624,229.44
atogepant	397	\$453,402.53

Physician Utilization

- Contrary to the pharmacy utilization, physician utilization top 20 has a greater variety of drugs.
- Gabapentin and pregabalin again dominate utilization and amount paid.

Generic Name	Bill Lines	Paid
PREGABALIN	677	\$184,317.42
GABAPENTIN	3,679	\$36,981.01
LACOSAMIDE	58	\$5,659.04
UBROGEPANT	2	\$3,344.43
RIMEGEPANT SULFATE	2	\$2,904.81
OXCARBAZEPINE	2	\$2,027.72
SUMATRIPTAN SUCCINATE	7	\$1,747.96
TOPIRAMATE	1	\$1,205.00
SUMATRIPTAN SUCC/NAPROXEN SOD	3	\$612.38

Committee Discussion

Public Comments

Drugs to Review and Other Projects

J. Kevin Gorospe, PharmD

DWC Consultant

Topics

- Biological drugs trend - will be working to pull this data for next meeting
- Drug categories the committee wants to review in detail
- Other P&T related projects and concerns

Committee Discussion

Public Comments

Review of Recommendations

Adjournment